BBB Therapeutics
Combines existing drugs with it's proprietary for enhanced drug delivery across the blood-brain barrier
21 employees · est. 2003 · Leiden, The Netherlands
Syntara
Syntara (ASX:SNT) is an ASX-listed clinical stage drug developer for diseases linked to fibrosis and inflammation.
58 employees · est. 1998 · Australia
Syntara is the older company (2003 vs 1998); Syntara is the larger of the two.
Side-by-Side Comparison
| Metric | BBB Therapeutics | Syntara |
|---|---|---|
| Founded | ||
| Founded | 2003 | 1998 older |
| Headquarters | ||
| Headquarters | Leiden, The Netherlands | Australia |
| Employees | ||
| Employees | 21 | 58 larger |
| Industry | ||
| Industry | Biopharma, Biotechnology, Pharmaceutical | Biotechnology, Health Care, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | Unknown | Post Ipo Equity |
| Total Funding | ||
| Total Funding | $21.00M | $1.39M |
| Funding Rounds | ||
| Funding Rounds | 7 | 1 |
| Services | ||
| Services | Not tracked yet | Not tracked yet |
| Target Customers | ||
| Target Customers | Not tracked yet | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Clinical Stage, Brain Disorders, Brain Cancer, Neuroinflammatory Diseases, Drug Development, G-Technology, Drug Delivery, Blood-brain Barrier, Clinical Trials, 2B3-101, 2B3-201, Phase IIa Trial, Phase I Clinical Study, Treatment | Clinical Stage Drug Development, Extracellular Matrix Dysfunction, Amine Oxidase Chemistry, Drug Candidates, Fibrotic Diseases, Inflammatory Diseases, Blood Cancers, Respiratory Products, Royalties, Neuroinflammation, Chronic Fibrosis, Haematological Malignancies, Myelofibrosis, Myelodysplastic Syndrome, Scar Management |
| Website | ||
| Website | bbbtherapeutics.com | syntaratx.com.au |
About BBB Therapeutics
BBB Therapeutics, founded in 2003 and headquartered in The Netherlands, is a clinical stage biotechnology company that has carved a niche in developing treatments for critical brain disorders, including brain cancer and neuroinflammatory diseases. The company leverages its proprietary G-TechnologyĂ...
About Syntara
Syntara (ASX:SNT) is a clinical stage drug developer focusing on diseases associated with fibrosis and inflammation. The company, founded in 1998, specializes in targeting extracellular matrix dysfunction using its expertise in amine oxidase chemistry. Its lead candidate SNT-5505 has received FDA Or...
Be first to know when either one moves
Funding rounds, hiring surges, leadership changes and stack switches at BBB Therapeutics and Syntara — tracked continuously, sent the day they land.
Funding, hiring, leadership and stack changes at BBB Therapeutics and Syntara — by email.
Frequently Asked Questions
Compare BBB Therapeutics with someone else
Start typing a company name or domain.